Small molecule targeted drugs for the treatment of rheumatoid arthritis include baricitib and tofacitib. Rheumatoid arthritis is an autoimmune disease with erosive arthritis as the main manifestation. Patients with this disease often experience morning stiffness, joint pain, joint swelling and other symptoms, and the treatment is based on medication, and surgery is needed when necessary. Targeted synthetic anti-rheumatic drugs belong to the category of optional drug therapy, common targeted synthetic drugs include Barettib and Tofacitib. Barettib and Tofacitib are JAK inhibitors, which can block most cytokines by inhibiting the JAK enzyme, thus relieving rheumatoid arthritis joint conditions. Drugs should be used under the guidance of a physician, and rheumatoid arthritis patients are advised to go to the rheumatology and immunology department of a regular hospital for detailed consultation.